Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment	Sanofi	Ongoing	amlitelimab	3	EFC17599	King Faisal Specialist Hospital and Research Center (Riyadh)
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease	Astrazeneca	Ongoing	Camizestrant (AZD9833)	3	8535C00001	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants with Type 2 Diabetes during Ramadan (T-RAM)	Eli Lilly	Ongoing	Tirzepatide	4	I8F-MC-GPIY	Al Moosa Specialized Hospital (al ahsa)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross over Study of Oral Deucrictibant Soft Capsule for On Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema	Pharvaris Netherlands B.V.	Ongoing	Deucrictibant	3	PHA022121-C306	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)	Janssen Research & Development	Ongoing	Nipocalimab	3	80202135EBF3001	King Faisal Specialist Hospital and Research Center (Riyadh), King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar)
Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study	King Abdullah International Medical Research Center’s (KAIMRC)	Ongoing	Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine	2	RJ19/119/J	King Abdullah Medical Complex (Jeddah)
A Randomized Controlled Trial Comparing Blood Glucose Control Intraoperative Between Insulin Drip vs. Insulin Boluses	King Faisal Specialist Hospital and Research Center (Jeddah)	Ongoing	Insulin	3	2023-45	King Faisal Specialist Hospital and Research Center (Jeddah)
The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency	Inozyme Pharma, Inc	Ongoing	INZ701	3	INZ701-106	King Faisal Specialist Hospital and Research Center (Riyadh)
Long-term pain and adherence observational study for Endometriosis treatment	Abbott	Ongoing	Duphaston	4	DYDR-522-0318	Dr.Arab Clinic
Real world Assessment of Dyslipidemia patients on Inclisiran effiCacy And toLerability: The RADICAL Study	Novartis	Ongoing	LEQVIO	4	CKJX839A1S	Dallah Hospital (Riyadh)